Alterations in Mitochondrial DNA in Corneal Fibroblast and Myofibroblast Post Injury

Nishant R Sinha1,2,3, Alexandria C Hofmann1,3, Laila A Suleiman2,3

  • 1Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri, United States.

Abstract

Insights

Mitochondrial DNA (mtDNA) quantity and mitochondrial transcription factor A (TFAM) are crucial in corneal fibrosis. TFAM modulation impacts corneal fibroblast to myofibroblast transdifferentiation, offering potential therapeutic targets for corneal injury.

Area of Science:

  • Cell Biology
  • Ophthalmology
  • Mitochondrial Biology

Background:

  • Mitochondria play a key role in cellular functions, but their specific involvement in corneal fibrosis remains unclear.
  • Corneal fibrosis, a leading cause of blindness, involves the transformation of corneal stromal fibroblasts into myofibroblasts.

Purpose of the Study:

  • To investigate the role of mitochondrial DNA (mtDNA) and mitochondrial transcription factor A (TFAM) in corneal fibrosis.
  • To examine changes in mtDNA and TFAM during the transdifferentiation of corneal stromal fibroblasts (CSFs) to corneal myofibroblasts (CMFs) in vitro and ex vivo.

Main Methods:

  • Utilized human corneal stromal fibroblasts (CSFs) and ex vivo human cornea models.
  • Induced corneal myofibroblast (CMF) formation using TGFβ1 (in vitro) and nitrogen mustard (NM) (ex vivo).
  • Employed gene editing techniques (CRISPR/Cas9), PCR, qRT-PCR, immunofluorescence, immunoblotting, and MitoSOX assays to analyze mtDNA, TFAM, αSMA, and reactive oxygen species (ROS).

Main Results:

  • CMFs exhibited significantly reduced mtDNA copies and mtDNA-to-nuclear DNA ratios compared to CSFs.
  • CSF to CMF transdifferentiation showed decreased TFAM and increased αSMA, mitochondrial ROS (mtROS), and ROS levels.
  • TFAM silencing inhibited fibrotic markers and increased mtDNA levels.
  • Nitrogen mustard-induced fibrotic corneas displayed reduced TFAM and elevated αSMA.

Conclusions:

  • Mitochondrial DNA plays a significant role in the transdifferentiation of corneal fibroblasts to myofibroblasts.
  • TFAM has the potential to modulate corneal fibrosis in injured corneas.
  • Further research is warranted to explore TFAM's therapeutic potential in corneal fibrotic diseases.